Processa Pharmaceuticals, Inc.
PCSA Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$1.81
KIRA · Stoqly’s AI analyst, in plain words
- Processa Pharmaceuticals, Inc. lost $13.6M in fiscal 2025.
Market cap
$5.0M
P/E
1.8x
Revenue
—
Net income
−$13.6M
Free cash flow
—
Operating margin
—
Processa Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$13.6M
No. It lost money last year.
How is the share priced?
1.8x
One share costs 1.8 times its yearly profit per share.
What Processa Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 18, 2026
- Legal name
- Processa Pharmaceuticals, Inc.
- CIK
- 0001533743
Processa Pharmaceuticals, Inc. · PCSA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $0.0M | — | — | — |
| Net income | −$11.4M | −$27.4M | −$11.1M | −$11.9M | −$13.6M |
| Diluted EPS | −$0.75 | −$34.05 | −$8.48 | −$96.78 | −$10.36 |
| Cash | |||||
| Cash from operations | −$8.7M | −$9.6M | −$8.1M | −$11.2M | −$11.4M |
| Capital expenditure | — | — | $0.0M | $0.0M | — |
| Free cash flow | — | — | −$8.1M | −$11.2M | — |
| Share count change | 104.3% | −94.7% | 62.8% | −90.7% | 969.7% |
| Debt and strength | |||||
| Cash and short-term investments | $16.5M | $6.5M | $4.7M | $1.2M | $5.5M |
| Shareholders' equity | $25.5M | $7.5M | $5.0M | $1.7M | $5.6M |
| Current ratio | 18.9x | 8.4x | 7.7x | 1.2x | 2.5x |
| Interest coverage | −30,333.8x | — | — | — | — |
| Returns and quality | |||||
| Return on equity | −47.2% | −166.4% | −178.5% | −354.5% | −373.0% |
| Return on tangible equity | −65.6% | −367.1% | −222.9% | −698.6% | −243.2% |
| Piotroski F-score | — | 2 | — | — | — |
| Altman Z'' | 24.0 | −33.3 | −43.6 | −111.3 | −48.6 |
Insiders bought, 12 months
$0.2M
9 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Processa Pharmaceuticals, Inc. · PCSA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.81 a share, the company is worth $5.0M: 1.8 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001533743). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.